Combining Novel Agents for CLL

Jennifer Brown, MD, PhD

Video Categories: CLL

Dr. Jennifer R. Brown talks about combining novel agents for treating CLL as the next step to achieve longer remissions for patients. Until now, novel agents have only been used individually or in combination with antibodies. New studies are being designed to measure the efficacy of combining novel agents with each other for improved outcomes.
July 13, 2021

Real-World Experience with TRK Inhibitors in Patients with Lung and Colon Cancers

Dr Mary Fidler of Rush University Medical Center, Chicago, IL, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, describe their practical experiences with TRK inhibitors in patients with lung cancer and colorectal cancer.

July 29, 2015

Assessing the Value of Cancer Treatments

Dr. Steve O’Day believes a treatment’s value incorporates combination of benefits, side-effects, and cost, stating that if the cost is high, we need to make sure the benefits are huge as well.